Summary Recently, many inhibitors of farnesyl protein transferase (FPTase) 
essential for the association of nuclear lamins with the nuclear envelope (Krohne et al, 1989; Hennekes and Nigg, 1994) . It has been demonstrated that the lamina, which consists primarily of lamins, stabilizes cell cycle-dependent chromatin structure (Gasser and Laemmli, 1986) and that lamins are required for the post-mitotic reassembly of the nuclear envelope (Burke and Gerace, 1986) . Thus, nuclear lamins play a key role in mitosis.
A number of studies have examined the FPTase inhibitors that may serve as effective antagonists of oncogenic Ras function in human cancers. These compounds can be divided into three groups: analogues of famesyl diphosphate (FPP) (Gibbs et al, 1993; Hara et al, 1993) , CAAX analogues (Goldstein et al, 1991; Brown et al, 1992; Garcia et al, 1993; James et al, 1993) and inhibitors with structures not resembling either FPP or the CAAX motif ( Van Der Pyl et al, 1992; Omura et al, 1993) . In particular, many of the compounds that have been demonstrated as being potent and selective inhibitors of FPTase activity in vitro and in vivo are CAAX analogues (Garcia et al, 1993; Kohl et al, 1993; James et al, 1993; Nagasu et al, 1995; Sepp-Lorenzino et al, 1995) . Although two enzymes responsible for prenylation, in addition to FPTase, have been isolated and characterized, i.e. geranylgeranyl protein transferase (GGPTase) I and II, these analogues show strong and preferential inhibition of FPTase. However, as nuclear lamins A and B are also farnesylated (Cox and Der, 1992) , FPTase inhibitors block farnesylation of nuclear lamins as well as that of Ras proteins (Garcia et al, 1993; James et al, 1993) and may perturb their function (Cox and Der, 1992) .
We wished to investigate whether manumycin, an analogue of FPP, and KT7595, a gliotoxin derivative, inhibit the cellular proliferation of human tumour cells that harbour multiple genetic abnormalities, whether the suppression is dependent on that of Ras farnesylation but not that of the function of nuclear lamins and whether the presence of activating mutations of Ras in human tumours is predictive of sensitivity to manumycin and KT7595. To address this question, we have used human colon carcinoma cells (LoVo), hepatoma cells (Mahlavu and PLC/PRF/5) and gastric carcinoma cells (KATO III) . In this report, we have demonstrated that inhibition of Ras farnesylation, but not of lamin function, leads to the inhibition of DNA synthesis and the anchorage-dependent and -independent growth of human tumour cell lines and that the presence of oncogenic Ras in human tumours is not predictive of sensitivity to manumycin and KT7595. These results led us to conclude that manumycin and KT7595 are effective inhibitors of Ras function and cellular proliferation, without disturbing lamin function in some human tumour cell lines. 
MATERIALS AND METHODS Materials

Preparation of manumycin and KT7595
Manumycin was dissolved to concentrations of 5, 10 and 15 mM in 100% dimethyl sulphoxide (DMSO). KT7595 was prepared at concentrations of 0.1 and 0.2 mm in 100% DMSO. They were stored unfiltered at -200C.
Cell culture
Mahlavu and PLC/PRF/5 were purchased from the American Type Culture Collection. LoVo and KATO III were provided by the Japanese Cancer Research Resources Bank. Mahlavu and PLC/PRF/5 were grown in minimal essential medium (MEM) containing 10% fetal calf serum (FCS). LoVo and KATO III were grown in Ham's F-12 and a 1:1 mixture of MEM and RPMI-1640 supplemented with 10% FCS respectively. In each assay, Dulbecco's modified Eagle medium (DMEM) supplemented with 10% FCS was used in all cell lines. The cell lines were maintained in 100-mm dishes at 370C in a humidified atmosphere (5% carbon dioxide, 95% air).
Measurement of DNA synthesis
The effect of manumycin and KT7595 on DNA synthesis was evaluated by [3H]thymidine incorporation. Mahlavu, PLC/PRF/5 and LoVo cells were placed at 3 x 103 per well on 96-well microplates (Coming). The medium was replaced with the fresh media containing various concentrations (5, 10 and 15 gM manumycin or 0.1 and 0.2,UM KT7595) and 0.1% DMSO 24 h after seeding. KATO III was also seeded at 1 x I04 per well (100,l) with the medium containing various concentrations (5, 10 and 15 gM manumycin or 0.1 and 0.2 gM KT7595) and 0.1% DMSO.
[3H]Thymidine (1 gCi per well) was added to the culture media 43 h after incubation (46 h after incubation for KATO III). The cells were harvested on glass filters using a semiautomatic cell harvester (1205 Betaplate) 48 h after incubation. The radioactivity of each cell sample was determined using a liquid scintillation counter.
Anchorage-dependent growth assays
Mahlavu, PLC/PRF/5 and LoVo cells were placed at 1.5 x 105 per 60-mm dish. One day after seeding, cultures were treated with increasing concentrations of manumycin or KT7595. KATO III was seeded at 1.5 x 105 per 60-mm dish with increasing concentrations of the drugs. After cells were treated for 24 h and 72 h with the drugs, cell counts were taken on triplicate dishes using a Coulter counter. Viability was assessed via trypan blue exclusion.
Anchorage-independent growth assays
For soft agar growth, 10 000 cells were seeded on a 35-mm dish in a 0.3% top agar layer over a 0.6% bottom agar layer. Drugs were included in both agar layers. Cultures were fed and treated with the drugs or vehicle twice weekly. Colonies more than 0.1 mm in diameter were scored manually from duplicate dishes after 12 days in culture.
DNA sequencing of H-, Ki-, and N-ras Fragments encompassing the region between codons 8 and 31 and the region between codons 54 and 75 were amplified using the polymerase chain reaction (PCR) technique in the N-ras gene. The primers used in the PCR were: N 1 2F (5'-GACTGAG-TACAAACTGGTGG-3') and N12R (5'-CTCTATGGTGGGAT-CATATT-3'), for amplifying the fragment of codons 8-31; and N61F (5'-GGTGAAACCTGTTTGTTGGA-3') and N61R (5'-ATACACAGAGGAAGCCTTCG-3'), for codons 54-75. The amplified fragments for sequencing analysis in the K-ras gene encompassed the region between codons 1 and 37 and the region between codons 45 and 74. The primers used to amplify the fragments were: K12F (5'-GTACTGGTGGAGTATTTGAT-3'), and K12R (5'-ACTCATGAAAATGGTCAGAG-3'), for codons 1-37; and K61F (5'-TTCCTACAGGAAGCAAGTAG-3') and K61R (5'-ACACAAAGAAAGCCCTCCCCA-3'), for codons 45-74. For the analysis of the H-ras gene, the amplified fragments encompassed the region between codons 8 and 15 and the region between 56 and 66. The primers for amplifying the fragments were: H12F (5'-GACGGAATATAAGCTGGTGG-3') and H12R (5'-TGGATGGTCAGCGCACTCTr-3'), for codons 8-15; and H61F (5'-AGACGTGCCTGTTGGACATC-3') and H61R (5'-CGCAT-GTACTGGTCCCGCAT-3') for codons 56-66. PCR was performed with 1 ,UM of each primer, using a Gene Amp kit (Perkin Elmer) with a 'Robocycler 40' PCR machine (Stratagene). Each PCR reaction cycle included denaturation at 94°C for 60 s, primer annealing at 56°C for 90 s and primer extension at 72°C for 90 s. PCR products were cloned in a TA cloning site of pT7-T Blue vector (Novagen) using T4 DNA ligase (Takara Syuzo). The sequence analysis of these PCR-amplified fragments in the cloning vector was performed using an ALFII automatic sequence analyser (Pharmacia) with M13 primers.
Ras farnesylation assay On day 0, Mahlavu and PLC/PRF/5 were seeded at a density of 8 x 105 per 100-mm dish. LoVo was seeded at 1.7 x 106 per 100-mm dish. On day 3, fresh media were changed. On day 4, the cells were re-fed with the medium supplemented with 10 M simvastatin. KATO III was seeded at a density of 3.5 x 106 per 60-mm dish in 3.5 ml of the medium supplemented with 10 ,UM simvastatin. After a 24-h incubation, the cells were then incubated for 4 h in fresh medium containing 15 ,uCi ml RS-[2-'4C]mevalonolactone (1.48-2.22 GBq mmol-') and 10 gM simvastatin in the absence or presence of 5, 10 and 15 ,UM manumycin or 0.1 and 0.2 ,UM KT7595. These cells were lysed with a buffer containing 10 mm sodium phosphate, dibasic, 154 mm sodium chloride, 12 mm sodium deoxycholate, 1 mm sodium fluoride, 0.1% sodium dodecyl sulphate (SDS), 31 mm sodium azide, 1% (v/v) Triton X-100, 1 mm phenylmethylsulfonyl fluoride, 0.15 ,u ml-aprotinin and 10 gg ml-1 leupeptin at 4°C for 10 min. After the cell extract was centrifuged for 10 min at 12 000 r.p.m., the supernatant was transferred to a new tube. Protein content was measured by the method of Lowry et al (1951) . Ras protein was immunoprecipitated from the cell extract with 10,l of an anti-v-Ha-ras (Ab-1) antibody (clone Y13-259)-protein A-agarose bead complex. The immunoprecipitated material was then analysed by SDS-PAGE using 5-20% acrylamide gels. Radiolabelled Ras protein was visualized by fluorography after intensification with Amplify fluorographic reagent (Amersham). The radioactivity was determined by a BAS-2000 Image Analyzer (Fuji Film, Tokyo, Japan).
Nuclear lamin farnesylation assay Farnesylation of nuclear lamins was measured in cell lines by a modification of the method of James et al (1993) . On day 0, Mahlavu and PLC/PRF/5 were seeded at a density of 3 x 105 per 60-mm dish. LoVo was seeded at 5 x 105 per 60-mm dish. On day 2, the cells were re-fed with the medium supplemented with 10 gM simvastatin. KATO III was seeded at a density of 2 x 106 per 35-mm dish in 2 ml of the medium supplemented with 10 gM simvastatin. After a 24-h incubation, the cells were then incubated for 4 h in fresh medium containing 15 gCi ml-1 RS-[2-14C]mevalonolactone (1.48-2.22 GBq mmol-') and 10,M simvastatin in the absence or presence of 5, 10 and 15 gM manumycin or 0.1 and 0.2 ,UM KT7595. The cells were disrupted in lysis buffer, after which a detergent-insoluble fraction (pellet) was prepared as described by James et al (1993) . The fraction was subjected to SDS-PAGE using 5-20% acrylamide gel. Radiolabelled proteins were visualized by fluorography after intensification with Amplify fluorographic reagent (Amersham).
Immunoblotting of lamin B
Cultures were treated with either vehicle, manumycin, KT7595 or 10 ,UM simvastatin for 20 h. Nuclear envelope fraction was isolated as described previously (Stick and Krohne, 1982; James et al, 1993) . The fraction was subjected to SDS-PAGE using 5-20% acrylamide gel. After transfer to Immobilon P membrane (Millipore), the blots were probed with mouse monoclonal antibody to lamin B (Oncogene Research Products). The Western blots were developed using enhanced chemiluminescence reagents (Amersham). 
RESULTS
We have previously shown that manumycin inhibits the growth of the human hepatome cell line Hep G2 via the suppression of Ras famesylation and that it retards human pancreatic cancer growth in nude mice . On the other hand, gliotoxin, which was isolated from the fermentation broth of a fungus, has been reported to inhibit FPTase in vitro ( Van Der Pyl et al, 1992) . KT7595 is a gliotoxin derivative (Figure 1 ), an inhibitor of FPTase that has an IC50 value of 7 ,UM in vitro (unpublished data).
EFFECT OF MANUMYCIN AND KT7595 ON DNA SYNTHESIS
The effect of manumycin and KT7595 on DNA synthesis of different cell lines is shown in Figure 2 (Figure 4) . PLC/PRF/5 and Mahlavu were more resistant than LoVo, although their clonogenicity was also inhibited dose-dependently (Figure 4) Figure 3B and D) . On the other hand, the growth of PLC/PRF/5 and Mahlavu cells was also inhibited, although the degree of the inhibition was less than that of LoVo ( Figure 3B and D). These three cell lines displayed a dose-dependent inhibition over the concentration range tested. Furthermore, the inhibition at each concentration was less at 24 h of treatment than at 72 h ( Figure 3A and C) . Thus, the cell proliferation of LoVo, PLC/PRF/5 and Mahlavu was inhibited by both drugs in dose-and time-dependent manners. The growth of KATO III was not affected at the tested concentrations of manumycin and KT7595 (Figure 3 ).
Ras farnesylation assay
To determine whether the inhibition of the cell growth depends on the inhibition of Ras famesylation, four cell lines labelled with effect of manumycin and KT7595 on farnesylation of nuclear lamins. The major proteins in the Triton-insoluble pellets are the nuclear lamins A and B (Figure 6 ), which have been reported to be famesylated (Wolda and Glomset, 1988; Beck et al, 1988; Farnsworth et al, 1989; Lutz et al, 1992; James et al, 1993) . In contrast to Ras famesylation, analysis of the modification of nuclear lamins showed that famesylation of these proteins was not affected by manumycin at the concentrations ranging from 5 to 15 ,UM in PLC/PRF/5, LoVo ( Figure 6 ) and Mahlavu (data not shown).
The lack of the inhibition of lamin farnesylation in KATO Ill (data not shown) was expected, because neither Ras famesylation nor the cell growth was inhibited in the cell line. Famesylation of nuclear lamins was not suppressed even in LoVo in which Ras farnesylation was markedly inhibited by approximately 80% at a concentration of 15 gM manumycin, although the intensity of the labelling of the famesylated lamins was much weaker for LoVo than for the other three cell lines ( Figure 6 ). KT7595, also, did not suppress famesylation of nuclear lamins in these four cell lines (data not shown).
Immunoblotting of lamin B Furthermore, we investigated the effect of these drugs on the modification of nuclear lamin in greater detail. For this purpose, we examined the lamin B in the nuclear envelope as farnesylation of lamin B promotes the association with the nuclear envelope (Farnsworth et al, 1989; Krohne et al, 1989; Hennekes and Nigg, 1994) . Lamin B in the nuclear envelope from LoVo cells treated with simvastatin, an inhibitor of isoprenoid biosynthesis, was suppressed compared with that derived from DMSO-treated cells (Figure 7) . However, incubation of LoVo cells with increasing concentrations of manumycin or KT7595 resulted in the inability of these drugs to retard lamin B in the nuclear envelope (Figure 7 ). In addition, there was no detectable retardation in the other three cell lines treated with these agents (data not shown).
Indirect immunofluorescence
The inhibition of lamin processing results in a distortion in nuclear lamina structure (Sinensky et al, 1990) . Moreover, the rearrangement of lamina structure is more sensitive than would be expected from the inhibition of lamin processing (Sinensky et al, 1990) . Therefore, we next examined the alteration in the nuclear lamina structure. As shown in Figure 8D , the marked disruption in lamina structure was observed by immunofluorescence in LoVo cells treated with simvastatin. However, indirect immunofluorescence of LoVo cells stained with antibody directed against the lamin B showed no perturbation of the lamina after treatment with 15 gM manumycin or 0.2 gM KT7595 (Figure 8 ). There was also no detectable structural rearrangement in the other three cell lines treated with these agents (data not shown).
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DISCUSSION
We have tested two members belonging to distinct groups among FPTase inhibitors on human cancer cell lines. They are manumycin, an analogue of FPP (Hara et al, 1993; Ito et al, 1996; Nagase et al, 1996) and KT7595, a gliotoxin derivative. Current data have demonstrated that these inhibitors can retard DNA synthesis and the anchorage-dependent and -independent growth via the suppression of Ras famesylation on human tumour cells (Figures 2-5 ). These data imply that even advanced tumours, which could harbour multiple genetic abnormalities in tumoursuppressor genes and in protooncogenes, require the function of Ras for cellular proliferation. However, the inhibition of Ras famesylation shown in Figure 5 is complicated because it is uncertain which of the three Ras proteins, K-, H-and N-Ras, is being analysed. Analyses have not been performed to determine whether manumycin or KT7595 shows an equivalent ability to block the processing of K-, H-and N-Ras or to determine which of the Ras proteins each cell line expresses. We have also shown that the presence of activating mutations of Ras in human tumours is not predictive of sensitivity to the FPTase inhibitors manumycin and KT7595. This conclusion is consistent with a previous study using a CAAX analogue (Sepp-Lorenzino et al, 1995) , although they have done the analysis on a wide spectrum of human tumours compared with our analysis of four cell lines. Moreover, Sepp-Lorenzino et al (1995) investigated the basis for the drug-resistant phenotype and suggested the presence of a rasindependent pathway for MAP kinase activation or the presence of alternate ras-related proteins, such as R-Ras2/TC21, in drug-resistant cell lines. It is likely, however, that the mechanism accounting for the resistance of KATO III for manumycin and KT7595 is different from the presence of a ras-independent pathway or alternate ras-related proteins. It is possible that manumycin and KT7595 are not capable of entering KATO III cells as both agents could not perturb Ras farmesylation (Figure 5 ), lamin famesylation and localization (data not shown), and protein prenylation (data not shown). The resistance to both compounds may also reflect that the predominant Ras protein expressed is K-Ras, which is very resistant to common FPTase inhibitors. However, it is interesting to know that manumycin can potently inhibit K-Ras processing in various epithelial cells and fibroblasts, including rat 3Y1 fibroblasts transformed with oncogenic (valine 12) K-Ras (K Akasaka et al, manuscript in preparation). Whether the differential sensitivity to these compounds is due to the difference in the permeability remains to be demonstrated using these radiolabelled FPTase inhibitors.
FPTase acts on the diverse substrates in distinct subcellular locales. In fact, in addition to the Ras proteins, at least eight other proteins have been reported to be famesylated (Gibbs et al, 1994) . In particular, nuclear lamins are important for cellular proliferation. For example, a high level of accumulation of prelamin A has been shown previously to inhibit the cell growth (Sinensky et al, 1994a) . It is not clear, therefore, whether the suppression of the function of nuclear lamins, besides that of Ras proteins, participates in the inhibition of the cellular growth. On the other hand, prenylation of nuclear lamins has been demonstrated to be compartmentalized entirely within the nucleus (Sinensky et al, 1991 (Sinensky et al, , 1994b Lutz et al, 1992) . As a consequence, it has been suggested that an inhibitor of FPTase may have differential activities on a variety of substrate proteins as a result of the subcellular locales (Garcia et al, 1993) .
The data presented here demonstrate that the inhibitors of FPTase manumycin and KT7595 could have a chemotherapeutic Table 1 Summary (Figures 6-8) . Moreover, these observations lead derived from human hepatocellular carcinoma, while the LoVo cell us to conclude that the deficit of the inhibitory effect of both agents line is from human colon adenocarcinoma.
British Journal of Cancer (1997) The major prenylated proteins in the Triton-insoluble pellet were identified as the nuclear lamins A and B (Beck et al, 1988; Wolda and Glomset, 1988; James et al, 1993) . They have been reported to be famesylated (Farnsworth et al, 1989; Cox and Der, 1992; Lutz et al, 1992; James et al, 1993) , like the modification of Ras. It has been suggested therefore that inhibitors of FPTase block not only farnesylation of Ras but also that of nuclear lamins and may also interrupt their function. The nuclear lamina, which is formed primarily by nuclear lamins, is one of the major structure components of the nuclear envelope (Gerace and Blobel, 1982; Gerace and Burke, 1988) . Farnesylation plays a critical role in promoting the association of the lamins with the nuclear envelope (Krohne et al, 1989; Hennekes and Nigg, 1994) . Several experiments have shown that nuclear lamins are essential for both the nuclear envelope reformation after mitosis (Burke and Gerace, 1986 ) and the post-mitotic reorganization of chromatin and the intranuclear architecture (Benavente and Krohne, 1986) . Thus, farnesylation of nuclear lamins is crucial for the cell proliferation. Prenylation of nuclear lamins has been suggested to be compartmentalized entirely within the nucleus (Sinensky et al, 1991 (Sinensky et al, , 1994b Lutz et al, 1992) . It is possible therefore that manumycin and KT7595 perturb farmesylation of Ras but not that of lamins because, to inhibit farnesylation of nuclear lamins, this compound needs to permeate not only the cell membrane but also the nuclear membrane. However, our results are not consistent with data showing that BZA-5B, one of the other FPTase inhibitors, abolishes detectable protein farnesylation but not farnesylationdependent biological processes (Dalton et al, 1995) . Whether this difference is inherent to each drug or common to an analogue of FPP, a gliotoxin derivative or an analogue of CAAX remains to be investigated. In summary, our experiments demonstrate that manumycin and KT7595, inhibitors of FPTase, can inhibit Ras farnesylation and the cell growth without disturbing farnesylation and localization of nuclear lamins. The observations made in this study with two different kinds of non-CAAX analogue inhibitors of FPTase may be similar to those made previously with other CAAX analogues; however, we think that it is pivotal to know whether the properties of the CAAX analogues also hold true for non-CAAX analogues, which interfere with the function of FPTase in a different fashion. Furthermore, this work using human-derived cell lines is significant because FPTase inhibitors show promise in the treatment of a diverse range of human malignancies.
